An open-label, multicenter study in male pediatric patients with cerebral X-linked Adrenoleukodystrophy (cALD) to assess the effect of MIN-102 treatment on disease progression prior to human stem cell transplant (HSCT)
Latest Information Update: 18 Dec 2024
At a glance
- Drugs Leriglitazone (Primary)
- Indications Adrenoleucodystrophy
- Focus Therapeutic Use
- Acronyms NEXUS
- Sponsors Minoryx Therapeutics
Most Recent Events
- 11 Dec 2024 According to a Minoryx Therapeutics media release, The company intend to file for European Marketing Authorization of leriglitazone in pediatric and adult cerebral Adrenoleukodystrophy (cALD) patients by mid-2025.
- 11 Dec 2024 Primary endpoint has been met. (arrested disease will be assessed at 24 weeks and at 96 weeks), according to Minoryx Therapeutics media release.
- 26 Jan 2024 According to a Minoryx Therapeutics media release, Minoryx and Neuraxpharm strongly believe that leriglitazone has a positive benefit-risk balance in patients with cALD. Result data from this ADVANCE study is now supported by 24 week data from NEXUS trial. Findings are being validated through confirmatory long term follow-up from ongoing trials NEXUS and CALYX, in adult patients with progressive cALD.